Cas:1160264-32-3 1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime manufacturer & supplier

Chemical Name:1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime

CAS.NO:1160264-32-3

Synonyms:1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime

Molecular Formula:C₈H₁₃N₃O₃

Molecular Weight:199.20712

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime Use and application,1-(2,2-dimethoxyethyl)-1H-imidazole-2-carbaldehyde oxime technical grade,usp/ep/jp grade.

Related News: Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. Glycine, L-leucylglycyl-L-phenylalanyl-L-alanyl- manufacturers “The jury was careful and awarded us what we’d asked for down to the penny,” Plexxikon’s lawyer Daralyn Durie told Bloomberg after the verdict came down. (4-bromo-2-fluorophenyl)-[2-[(4-methylpiperazin-1-yl)methyl]phenyl]methanone suppliers Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. Disulfide, bis[(1S)-3-(4-methoxyphenyl)-1-methylpropyl] vendor & factory Its approval has since been called into question, however, and the head of the FDA is now calling for a federal investigation looking into interactions between agency staff and the biotech company.,McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019.